Intrahepatic delivery of α-galactosylceramide-pulsed dendritic cells suppresses liver tumor

Hepatology

Volumn 45, Issue 1, 2007, Pages 22-30

  Tatsumi, Tomohide ^a   Takehara, Tetsuo ^a   Yamaguchi, Shinjiro ^a   Sasakawa, Akira ^a   Sakamori, Ryotaro ^a   Ohkawa, Kazuyoshi ^a   Kohga, Keisuke ^a   Uemura, Akio ^a   Hayashi, Norio ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; GAMMA INTERFERON; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG PULSE THERAPY; FEMALE; IN VIVO STUDY; LIVER TUMOR; MOUSE; NATURAL KILLER CELL; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR REJECTION;

ANIMALS; CELL COMMUNICATION; CELL LINE, TUMOR; CELL PROLIFERATION; DENDRITIC CELLS; FEMALE; GALACTOSYLCERAMIDES; IMMUNITY, NATURAL; IMMUNOTHERAPY; INJECTIONS; INTERFERON TYPE II; KILLER CELLS, NATURAL; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; TISSUE THERAPY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33846413504     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21447     Document Type: Article

References (41)

1. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991;9:271-296.
2. Hart DN. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997;90:3245-3287.
3. O'Neill DW, Adams S, Bhardwaj N. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 2004;104:2235-2246.
4. Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Beller D, Suter M, et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 1999; 5:405-411.
5. Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G, Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 2002;195:327-333.
6. Ferlazzo G, Tsang ML, Moretta L, Melioli G, Steinman RM, Munz C. Human dendritic cells activate resting NK cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med 2002;195:343-351.
7. Piccioli D, Sbrana S, Melandri E, Valiante NM. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med 2002;195:335-341.
8. Miller G, Lahrs S, Dematteo RP. Overexpression of interleukin-12 enables dendritic cells to activate NK cells and confer systemic antitumor immunity. FASEB J 2003;17:728-730.
9. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki H, et al. CD1d-restricted and TCR-mediated activation of Vα14NKT cells by glycosylceramides. Science 1997;278:1626-1629.
10. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko K, Sato H, et al. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Vα14NKT cells. Proc Natl Acad Sci U S A 1998;95:5690-5693.
11. Kitamura H, Iwakabe K, Yahata T, Nishimura S, Ohta A, Ohmi S, et al. The natural killer T (NKT) cell ligand α-galactosylceramide demonstrates its immunopoteniating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med 1999;189:1121-1128.
12. Doherty DG, O'Farrelly C. Innate and adaptive lymphoid cells in human liver. Immunol Rev 2000;174:5-20.
13. Mehal WZ, Azzaroli F, Crispe IN. Immunology of the healthy liver: Old questions and new insights. Gastroenterology 2001;120:250-260.
14. Ladhams A, Schmidt C, Sing G, Butterworth L, Fielding G, Tesar P, et al. Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells. J Gastroenterol Hepatol 2002;17:889-896.
15. Iwashita Y, Tahara K, Goto S, Sasaki A, Kai S, Seike M, et al. A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer. Cancer Immunol Immunother 2003;52: 155-161.
16. Chi KH, Liu SJ, Li CP, Kuo HP, Wang YS, Chao Y, et al. Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J Immunother 2005;28:129-135.
17. Lee WC, Wang HC, Hung CF, Huang PF, Lia CR, Chen MF. Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendrite cells: a clinical trial. J Immunother 2005;28:496-504.
18. Fujii S, Shimizu K, Kronenberg M, Steinman RM. Prolonged IFN-γ-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat Immunol 2002;3:867-874.
19. Gonzalez-Aseguinolaza G, de Oliveira C, Tomaska M, Hong S, Bruna-Romero O, Nakayama T, et al. α-Galactosylceramide-activated Vα 14 natural killer T cells mediate protection against murine malaria. Proc Natl Acad Sci U S A 2000;97:8461-8466.
20. Miyagi T, Takehara T, Tatsumi T, Kanto T, Suzuki T, Jinushi M, et al. CD1d-mediated stimulation of natural killer T cells selectively activates hepatic natural killer cells to eliminate experimentally disseminated hepatoma cells in murine liver. Int J Cancer 2003;106:81-89.
21. Nakagawa R, Motoki K, Ueno H, Iijima R, Nakamura H, Kobayashi E, et al. Treatment of hepatic metastasis of the colon26 adenocacinoma with an α-galactosylceramide, KRN7000. Cancer Res 1998;58:1202-1207.
22. Toura I, Kawano T, Akutsu Y, Nakayama T, Ochiai T, Taniguchi M. Inhibition of experimental tumor metastasis by dendritic cells pulsed with α-galactosylceramide. J Immunol 1999;163:2387-2391.
23. Nieda M, Okai M, Tazbirkova A, Lin H, Yamaura A, Ide K, et al. Therapeutic activation of Vα24+Vβ11+NKT cells in human subjects results in highly coordinates secondary activation of acquired and innate immunity. Blood 2004;103:383-389.
24. Giaccone G, Punt CJ, Ando Y, Ruijter R, Nishi N, Peters M, et al. A phase I study of the natural killer T-cell ligand α-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 2002;8:3702-3709.
25. Ishikawa A, Motohashi S, Ishikawa E, Fuchida H, Higashino K, Otsuji M, et al. A phase I study of α-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 2005;11:1910-1917.
26. Chang DH, Osman K, Connolly J, Kukreja A, Krasovsky J, Pack M, et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med 2005;201:1503-1517.
27. Chiodoni C, Stoppacciaro A, Sangaletti S, Gri G, Cappetti B, Koezuka Y, et al. Different requirements for α-galactosylceramide and recombinant interleukin-12 antitumor activity in the treatment of C-26 colon carcinoma hepatic metastases. Eur J Immunol 2001;31:3101-3110.
28. Mayordomo JI, Loftus DJ, Sakamoto H, De Cesare CM, Appasamy PM, Lotze MT, et al. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med 1996;183:1357-1365.
29. Tatsumi T, Huang J, Gooding WE, Gambotto A, Robbins PD, Vujanovic NL, et al. Intratumoral delivery of dendritic cells engineered to secrete both interleukin(IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. Cancer Res 2003; 63:6378-6386.
30. Porgador A, Snyder D, Gilboa E. Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol 1996;156: 2918-2926.
31. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD Jr, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptide elicits protective and therapeutic antitumor immunity. Nat Med 1995;12:1297-1302.
32. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52-58.
33. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-332.
34. Salgaller ML, Tjoa BA, Lodge PA, Ragde H, Kenny G, Boynton A, et al. Dendritic cell-based immunotherapy of prostate cancer. Crit Rev Immunol 1998;18:109-119.
35. Ferlazzo G, Munz C. NK cell compartments and their activation by dendritic cells. J Immunol 2004;172:1333-1339.
36. Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996;183:87-97.
37. Osman Y, Kawamura T, Naito T, Takeda K, Van Kaer L, Okumura K, et al. Activation of hepatic NKT cells and subsequent liver injury following administration of α-galactosylceramide. Eur J Immunol 2000;30:1919-1928.
38. Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman RM. Activation of natural killer T cells by α-gatactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med 2003;198:267-279.
39. Fujii S, Liu K, Smith C, Bonito AJ, Steinman RM. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J Exp Med 2004;199:1607-1618.
40. Hermans IF, Silk JD, Gileadi U, Salio M, Mathew B, Ritter G, et al. NKT cells enhance CD4+ and CD8+ T cells responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol 2003;171: 5140-5147.
41. Nishimura T, Kitamura H, Iwakabe K, Yahata T, Ohta A, Sato M, et al. The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes. Int Immunol 2000;12:987-994.